The Top 5 Biosimilar Articles for the Week of October 4

Here are the top 5 biosimilar articles for the week of October 4, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 4, 2021.

Number 5: Sonia T. Oskouei, PharmD, BCMAS, DPLA, the vice president of Biosimilars at Cardinal Health, discussed the many ways that pharmacists and interchangeability designations can affect biosimilar utilization.

Number 4: Investigators reported positive findings from 2 studies of patients with inflammatory bowel disease (IBD) who switched from intravenous administration of the infliximab biosimilar Remsima (CT-P13) to subcutaneous administration.

Number 3: Preventing the nocebo effect requires a demonstration of confidence in biosimilars from all health care practitioners, including pharmacists, experts said in a newly published rheumatology treatment guidance document.

Number 2: Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, talked about the savings that biosimilars have brought to his practice and how he tackles patient and physician concerns over whether biosimilars work as well as reference products.

Number 1: Adrian van den Hoven, director general for Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, discussed the group’s recent EU report: Market Review—Biosimilar Medicine Markets.

To read all of these articles and more, visit centerforbiosimilars.com.